The once-daily combination drop is approved by the FDA to treat presbyopia.
News|Articles|October 23, 2026
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
Author(s)Martin David Harp
In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at-home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.
Advertisement
Advertisement
October 16, 2026, delivered 3 ophthalmic FDA approvals that, taken together, touch nearly every corner of the eye care practice, from the patient browsing a pharmacy aisle to the oculoplastic surgeon managing a rare autoimmune orbitopathy.
Related to this article
The half-life extended FcRn inhibitor showed a 74% peak reduction in IgG in healthy volunteers.
The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.
The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.
Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.
R. Ross Lakhanpal, MD, FACS, Anu Patel, MD, and Yasha S. Modi, MD, MHS, point to cell replacement in geographic atrophy, care burden, and glycemic control.
Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME
The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.
Advertisement
Advertisement